Aphria (NASDAQ:APHA) Inc.’s APHA fiscal fourth-quarter 2020 results are scheduled to release on Jul 29, after the closing bell. In the last reported quarter, the company delivered earnings surprise of 150%.
Q4 Estimates
The Zacks Consensus Estimate for fiscal fourth-quarter revenues is pegged at $102.3 million, indicating an improvement of 6.4% from the year-ago reported figure.
Factors to Note
Higher demand of medical and adult-use cannabis products is likely to have contributed to Aphria’s net revenues in the to-be-reported quarter attributable to. Per the fiscal third-quarter earnings call, cannabis consumption has returned to a more normalized pre-COVID-19 levels for all regions with the exception of Quebec where cannabis sales remain at an even higher level.
This, in turn, might have benefited the company’s fiscal fourth-quarter performance.
Aphria is likely to have gained from an enhanced global team, brand-building activities, new facility and production abilities, and investment in new systems and technology.
In the fiscal third quarter, the company exhibited its strength as a leading producer with both Aphria One and Aphria Diamond being fully licensed and operating at full capacity. Consequently, this may get reflected on the company’s fiscal fourth-quarter results.
Aphria possesses compelling brands for patients and consumers across broad demographics, which includes five high-quality brands including Solei RIFF, Good Supply, Broken Coast and Aphria medical brand. These are likely to have favored the company’s fiscal fourth-quarter performance.
During the fiscal third quarter, the company received its European Union Good Manufacturing Practices (EU GMP) certification from the Malta Medicines Authority ("MMA") at the company’s subsidiary, ARA - Avanti Rx Analytics and GMP annex at the Aphria One facility. This enabled Aphria to commence supply of medical cannabis throughout the European Union and bolstered its international export capabilities.
This might have positively impacted the company’s performance in the to-be-reported quarter.
Here’s What the Quantitative Model Suggests
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: Aphria has an Earnings ESP of -66.67%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aphria carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Integra LifeSciences Holdings Corporation IART has an Earnings ESP of +20.69% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exact Sciences (NASDAQ:EXAS) Corporation EXAS has an Earnings ESP of +6.69% and a Zacks Rank of 2.
Hologic (NASDAQ:HOLX), Inc. HOLX has an Earnings ESP of +14.56% and a Zacks Rank of 3.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis Report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report
Exact Sciences Corporation (EXAS): Free Stock Analysis Report
Aphria Inc. (APHA): Free Stock Analysis Report
To read this article on Zacks.com click here.